Impact of Ga-68 DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia

Annals of Nuclear Medicine

Volumn 26, Issue 9, 2012, Pages 738-743

  Froeling, Vera ^a   Elgeti, Florian ^a   Maurer, Martin H ^a   Scheurig Muenkler, Christian ^a   Beck, Alexander ^a   Kroencke, Thomas J ^a   Pape, Ulrich Frank ^a   Hamm, Bernd ^a   Brenner, Winfried ^a   Schreiter, Nils F ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Ga 68 DOTATOC PET CT; Multiple endocrine neoplasia; Therapeutic management

Indexed keywords

RADIOPHARMACEUTICAL AGENT; TETRAXETAN DEXTRO 1 PHENYL 3 TYROSINE OCTREOTIDE GALLIUM GA 68; UNCLASSIFIED DRUG;

ADOLESCENT; ADRENAL GLAND; ADULT; AGED; ARTICLE; BONE TUMOR; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC VALUE; FEMALE; GASTROINTESTINAL TUMOR; HUMAN; LIVER TUMOR; LUNG TUMOR; LYMPH NODE METASTASIS; LYMPHOMA; MALE; MULTIPLE ENDOCRINE NEOPLASIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS TUMOR; PARATHYROID ADENOMA; PARATHYROID TUMOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TUMOR DIAGNOSIS; TUMOR LOCALIZATION;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84872117156     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-012-0634-z     Document Type: Article

References (22)

1. Marini F, Falchetti A, Del Monte F, Carbonell Sala S, Gozzini A, Luzi E, et al. Multiple endocrine neoplasia type 1. Orphanet J Rare Dis. 2006;2:1-38.
2. Schussheim DH, Skarulis MC, Agarwal SK, Simonds WF, Burns AL, Spiegel AM, et al. Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends EndocrinolMetab. 2001;12:173-8. (Pubitemid 33713559)
3. Iler MA, King DR, Ginn-Pease ME, O'Dorisio TM, Sotos JF. Multiple endocrine neoplasia type 2A: a 25-year review. J Pediatr Surg. 1999;34:92-6.
4. Raue F, Frank-Raue K. Update multiple endocrine neoplasia type 2. Fam Cancer. 2010;9:449-57.
5. Georgitsi M. MEN-4 and other multiple endocrine neoplasias due to cyclin-dependent kinase inhibitors (p27(Kip1) and p18(INK4C)) mutations. Best Pract Res Clin Endocrinol Metab. 2010;24:425-37.
6. Pacak K, Eisenhofer G, Goldstein DS. Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev. 2004;25:568-80.
7. Ruf J, Heuck F, Schiefer J, Denecke T, Elgeti F, Pascher A, et al. Impact of Multiphase 68 Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. Neuroendocrinology. 2010;91:101-9.
8. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658-71.
9. Zhernosekov KP, Filosofov DV, Baum RP, Aschoff P, Bihl H, Razbash AA, et al. Processing of generator-produced 68 Ga for medical application. J Nucl Med. 2007;48:1741-8.
10. Breeman WA, de Jong M, de Blois E, Bernard BF, Konijnenberg M, Krenning EP. Radiolabelling DOTA-peptides with 68 Ga. Eur J Nucl Med Mol Imaging. 2005;32:478-85.
11. Pfannenberg C, Schraml C, Schwenzer N, Werner M, Muller M, Bares R, et al. Comparison of [68 Ga]DOTATOC-PET/CT and whole-body MRI in staging of neuroendocrine tumors. Cancer Imaging. 2011;11:38-9.
12. Paulson EK, McDermott VG, Keogan MT, DeLong DM, Frederick MG, Nelson RC. Carcinoid metastases to the liver: role of triple-phase helical CT. Radiology. 1998;206:143-50.
13. Caplin M, Sundin A, Nillson O, Baum RP, Klose KJ, Kelestimur F, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology. 2012;95:88-97.
14. Pelage JP, Soyer P, Boudiaf M, Brocheriou-Spelle I, Dufresne AC, Coumbaras J, et al. Carcinoid tumors of the abdomen: CT features. Abdom Imaging. 1999;24:240-5. (Pubitemid 29215354)
15. Ruf J, Schiefer J, Furth C, Kosiek O, Kropf S, Heuck F, et al. 68 Ga-DOTATOC PET/CT of neuroendocrine tumors: spotlight on the CT phases of a triple-phase protocol. J Nucl Med. 2011; 52:697-704.
16. Mayerhoefer ME, Schuetz M, Magnaldi S, Weber M, Trattnig S, Karanikas G. Are contrast media required for (68)Ga-DOTATOC PET/CT in patients with neuroendocrine tumours of the abdomen? Eur Radiol. 2012;22:938-46.
17. Pasquali C, Rubello D, Sperti C, Gasparoni P, Liessi G, Chierichetti F, et al. Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J Surg. 1998;22:588-92.
18. Marzola MC, Pelizzo MR, Ferdeghini M, Toniato A, Massaro A, Ambrosini V, et al. Dual PET/CT with (18)F-DOPA and (18)FFDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: comparison with conventional imaging. Eur J Surg Oncol. 2010;36:414-21.
19. Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. E Eur J Nucl Med. 2001;28:1671-6. (Pubitemid 33036110)
20. Szakall S Jr, Esik O, Bajzik G, Repa I, Dabasi G, Sinkovics I, et al. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med. 2002;43:66-71.
21. Weber T, Cammerer G, Schick C, Solbach C, Hillenbrand A, Barth TF, et al. C-11 methionine positron emission tomography/ computed tomography localizes parathyroid adenomas in primary hyperparathyroidism. Horm Metab Res. 2010;42:209-14.
22. Li S, Beheshti M. The radionuclide molecular imaging and therapy of neuroendocrine tumors. Curr Cancer Drug Targets. 2005;5:139-48.